Tech Company Financing Transactions
C2i Genomics Funding Round
On 4/17/2021, C2i Genomics received $100 million in Series B funding from Casdin Capital, Driehaus Capital Management and Duquesne Capital Management.
Transaction Overview
Company Name
Announced On
4/17/2021
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Casdin Capital (Lead Investor) (Eli Casdin)
NFX (James Currier)
Proceeds Purpose
The funds will be used to accelerate clinical development and commercialization of the company's C2 Intelligence platform, cancer diagnostics tool that uses artificial intelligence (AI) recognition and whole genome analysis to rapidly detect tiny traces of residual disease in patients' blood.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
180 Varick St. 6th Floor
New York, NY 10014
USA
New York, NY 10014
USA
Phone
Undisclosed
Website
Email Address
Overview
C2i was formally founded in 2019 and is based on technology developed at Cornell and the New York Genome Center. We are backed by private investors. Our Company is headquartered in the US with an R&D center in Israel. We brought in the same outstanding people who developed the technology in academia, to build a successful team rapidly.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Asaf Zviran
Chief Financial Officer
Ezra Sofer
Chief Technical Officer
Boris Oklander
VP - Bus. Development
Mark Oldroyd
VP - R & D
Ravi Kandasamy
Browse more venture capital transactions:
Prev: 4/17/2021: Torch Freight venture capital transaction
Next: 4/17/2021: Chain.io venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs